^
Association details:
| Biomarker: | NRAS Q61K |
|---|---|
| Cancer: | Melanoma |
| Drug: | SBI-756 (AKT inhibitor, mTORC1 inhibitor, NF-κB inhibitor, eIF4G1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SBI-0640756 attenuates the growth of clinically unresponsive melanomas by disrupting the eIF4F translation initiation complex
Excerpt:
In vivo we first evaluated SBI-756 using an inducible NrasQ61K/Ink4a–/– genetic model in which melanoma tumors emerge within 16–20 weeks (Fig. 4B). Administration of SBI-756 only, starting 11 weeks after genetic inactivation of Ink4a and induction of NRasQ61E (about 10–14 days prior to tumor appearance), delayed tumor onset (from 20–26 weeks) and reduced tumor incidence, by 50%, compared with the control non-treated group.
DOI:
10.1158/0008-5472.CAN-15-0885
